STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

Related Keywords

United States ,San Antonio ,Texas ,Chicago ,Illinois ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Justin Moser ,Jordi Rodon Ahnert ,Kyriakos Papadopoulos ,Josefin Beate Holz ,Honorhealth Research Institute ,American Society Of Clinical Oncology ,Therapeutics Ltd ,Storm Therapeutics Ltd ,Ip Group ,Utokyo Innovation Platform Co Ltd ,Fast Track Initiative ,Justin Moser At Honorhealth Research Institute ,Seroba Life Sciences ,Cambridge Innovation Capital ,University Of Texas Md Anderson Cancer Center ,Taiho Ventures ,American Society ,Clinical Oncology ,Annual Meeting ,Cohort Expansion Study Evaluating Safety ,Clinical Activity ,Advanced Malignancies ,Honorhealth Research ,Jordi Rodon ,Health Research Institute ,Cancer Center ,Saturday June ,Board Number ,Presentation Number ,Pfizer Ventures ,Cambridge Innovation Capital Limited ,Ihr Portfolio ,